Autolus Therapeutics
AUTL
46 hedge funds and large institutions have $344M invested in Autolus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 4 closing their positions.
489% more capital inflows, than outflows
Capital inflows: $88.5M | Capital outflows: $15M
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
31% more funds holding
Funds holding: 35 → 46 (+11)
4.52% more ownership
Funds ownership: 24.81% → 29.33% (+4.5%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$23.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.36M |
| 4 |
Millennium Management
New York
|
+$7.1M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodford Investment Management
London,
United Kingdom
|
-$10M |
| 2 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.35M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
-$378K |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$345K |
| 5 |
Alphabet Inc
Mountain View,
California
|
-$329K |
AUTL Hedge Fund Activity: Q2 2019 in Review
46 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2019, worth a combined $344M — down 40% from $569M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AUTL positions and 4 closed out — a net gain of 11 holders — while 21 added to existing stakes and 6 trimmed.
The largest buyer was Capital World Investors, adding an estimated $23.8M. The largest seller was Woodford Investment Management, cutting an estimated $10M.
- 46 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2019, up from 35 in Q1 2019.
- Funds reported $344M of Autolus Therapeutics stock for Q2 2019, down 40% quarter-over-quarter.
- 15 funds opened new Autolus Therapeutics positions in Q2 2019 and 4 closed out, a net change of +11 holders.
- The largest Autolus Therapeutics buyer in Q2 2019 was Capital World Investors, an estimated $23.8M added.
- The largest Autolus Therapeutics seller in Q2 2019 was Woodford Investment Management, an estimated $10M sold.
Based on aggregated 13F filings for Q2 2019.